So far, several HDAC inhibitors have undergoneclinical trials, with five receiving FDA approval for cancer treatments(vorinostat, panobinostat, romidepsin, and belinostat) and for thetreatment of Duchenne muscular dystrophy (givinostat). The gene discussed is HDAC9; the disease is cancer.